November 15, 2011 — A new clinical trial is testing the efficacy of rotational atherectomy (or rotablation, a process of ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
November 15, 2011 — A clinical trial has shown a drug-eluting stent (DES) with a bioabsorbable polymer has comparable ...
November 14, 2011 – OrbusNeich announced the introduction of the Combo dual therapy stent during a breakfast symposium ...
November 14, 2011 – The TWENTE clinical trial, which compared Resolute versus Xience V drug-eluting stents in a real ...
November 11, 2011 – Boston Scientific reported results from the EVOLVE first human use trial demonstrating the non ...
November 11, 2011 – Biosensors International Group announced two-year results from the BioFreedom first-in-human trial ...
November 9, 2011 — Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute drug-eluting ...
November 8, 2011 — Biosensors International Group Ltd. announced final results of the AXXESS PLUS trial, which ...
November 8, 2011 – Boston Scientific reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating ...
November 7, 2011 – Abbott announced the company's schedule of key data presentations at the 23rd annual Transcatheter ...
Nov. 2, 2011 – The U.S. Food and Drug Administration (FDA) granted market clearance for the Xience Prime everolimus ...
November 1, 2011 – Boston Scientific released the schedule of its major events and product-related clinical research for ...
October 18, 2011 — Boston Scientific Corp. has begun a phased launch of its Promus Element everolimus-eluting platinum ...
October 14, 2011 – A U.S. Food and Drug Administration (FDA) review panel gave its unanimous recommendation for the ...
The Holy Grail sought for more than two decades by interventional cardiology has been proof that minimally invasive ...